查看購物車
  • English
  • Japanese
封面
市場調查報告書
商品編碼
2016896

移植診斷市場：按診斷應用、技術、器官類型和最終用戶分類的全球市場預測 – 2026-2032 年

Transplant Diagnostics Market by Diagnostic Application, Technology, Organ Type, End User - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 192 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計到 2025 年，移植診斷市值將達到 67.8 億美元，到 2026 年將成長到 72 億美元，到 2032 年將達到 109.2 億美元，複合年成長率為 7.03%。

主要市場統計數據
基準年 2025 67.8億美元
預計年份：2026年 72億美元
預測年份 2032 109.2億美元
複合年成長率 (%) 7.03%

全面介紹移植診斷，說明分子層級創新、臨床工作流程和指導治療途徑的監管要求之間的交會點。

移植診斷處於免疫學、分子生物學和臨床工作流程最佳化的關鍵交叉點，快速可靠的診斷是患者預後和計畫永續性的基礎。分子檢測、次世代定序和數位PCR的最新進展擴展了臨床醫生和檢查室管理人員可用的診斷工具，從而能夠更精準地進行捐贈者-受體匹配、更早發現移植失敗並加強病原體監測。這些技術進步與強調快速週轉、自動化數據整合和可擴展檢查室模式的營運趨勢相輔相成，這些趨勢支持高通量檢測，同時又不影響分析的嚴謹性。

新的分子診斷平台、數位整合和協作證據產生如何改變移植診斷的臨床實踐和應用路徑？

隨著新興技術、數據驅動的醫療模式和不斷演進的臨床方案的整合並重新定義標準實踐，移植診斷的格局正在改變。首先，分子診斷正從單一檢測轉向多項檢測和基於定序的方法，從而提供更詳細的免疫遺傳學和病原體譜。這種轉變正在改變移植團隊選擇捐贈者、免疫抑制管理和移植後追蹤的方式，因為臨床醫生現在可以觀察生物標記後續觀察時間推移的演變，而不是孤立的簡介。

評估近期美國關稅措施對移植診斷的採購、製造和臨床工作流程的營運和供應鏈影響。

美國2025年實施的關稅政策進一步加劇了依賴全球供應鏈的製造商、檢查室和臨床計畫的複雜性。依賴進口的組件，例如專用試劑、儀器零件和定序耗材，正面臨採購成本上升和採購計畫中斷的雙重困境。因此，檢查室管理人員必須重新評估與供應商的關係，以實現供應商網路多元化，並在某些情況下優先考慮安全庫存，以維持偵測服務的連續性。

深入的細分分析揭示了診斷應用、技術模式、器官特定需求和最終用戶結構如何影響採用和投資重點。

對市場區隔的深入理解能夠提供切實可行的洞見，幫助我們了解臨床需求和技術應用趨勢的差異。從診斷角度來看，供受者配對、移植監測、 HLA型檢測和傳染病篩檢各自佔據不同的臨床路徑，具有不同的分析重點。在HLA型檢測中，解析度需求存在雙重性。高解析度檢測能夠在複雜病例中實現精確的等位基因水平配型，而低解析度方法則繼續滿足常規相容性篩檢的需求。傳染病篩檢涵蓋細菌、真菌和病毒領域，病毒監測本身需要針對巨細胞病毒、 EB病毒、肝炎病毒和HIV等病原體進行標靶檢測，每種病原體都對檢查室的靈敏度和反應時間提出了特定的要求。

此區域分析詳細闡述了臨床能力、監管多樣性和供應鏈趨勢如何影響全球醫療保健市場採用模式的差異。

了解區域趨勢對於理解臨床實踐、法規結構和報銷政策如何影響移植醫學中診斷技術的應用至關重要。在美洲，臨床網路和中心檢查室通常優先考慮快速分子檢測和精簡的供應鏈，而大型移植中心則作為早期採用者和標桿，影響全國的醫療實踐。在歐洲、中東和非洲，不同的法規環境、報銷機制和檢查室基礎設施導致了廣泛的技術應用率頻譜，無論是先進的醫療實踐還是資源有限的環境，都優先考慮經濟高效且可靠的檢測方法。在亞太地區，對檢測能力的快速投資，加上臨床病例的增加以及對本土生產的重視，正在加速定序和基於PCR的診斷技術的應用，尤其是在都市區三級醫療機構中。

以專業創新者、平台供應商和資訊解決方案之間的互動為重點的競爭格局分析。

移植診斷領域的競爭動態體現了利基創新企業與大規模平台供應商之間的平衡，後者提供涵蓋檢測、儀器和資訊學的一體化解決方案。利基企業通常在檢測創新方面發揮主導作用，提供高解析度HLA型檢測、標靶病毒監測以及針對特定未滿足臨床需求的新型生物標記方法。相較之下，大型企業則利用規模經濟，投資於檢查室自動化、全球分銷網路和監管合規項目，促進更廣泛的市場滲透。檢測開發人員、儀器製造商和臨床網路之間的夥伴關係與策略聯盟日益普遍，為檢驗臨床效用和透過現有管道加速推廣提供了途徑。

為診斷開發人員、檢查室和臨床領導者提供實用建議，以使證據產生、互通性和強大的供應策略與推廣目標保持一致。

行業領導者應優先考慮證據生成、互通性和供應鏈韌性，以將技術潛力轉化為常規臨床實踐。首先，新診斷方法的申辦者必須投資於嚴格的臨床檢驗試驗和真實世界證據（RWE）項目，以證明其在具有代表性的移植患者群體和各種醫療環境中的臨床效用。這種方法有助於制定合理的使用指南，同時增強臨床醫生的信心並促進支付方的參與。其次，供應商和實驗室在設計時應考慮互通性，採用標準化的報告格式、電子健康記錄應用程式介面（API）以及與實驗室資訊系統的整合。這可以降低採用門檻，並實現跨醫院網路的可擴展部署。

透明嚴謹的調查方法結合了臨床文獻、監管指南和該領域醫療保健專業人員的見解，以支持實證結論。

本執行摘要的研究整合了同行評審文獻、監管指南、官方臨床指南以及近期行業資訊披露，以確保提供平衡且基於證據的觀點。主要資料來源包括臨床檢驗研究、檢測性能報告以及說明檢測方法和分析特性的技術白皮書。研究人員仔細審查了監管和指導文件，以了解檢驗、報告和檢查室品質保證方面不斷變化的要求。此外，還納入了實驗室主任、移植臨床醫生和供應鏈經理的定性回饋，以反映有關實施、週轉和採購方面的實際考慮因素。

該摘要強調了技術成熟度、營運韌性和協作證據產生將如何決定移植診斷的臨床影響和傳播軌跡。

先進的分子技術、檢查室自動化程度的提升以及臨床期望的不斷提高，共同使得移植診斷成為改善移植效果和增強病患安全的關鍵要素。從供體選擇、 HLA型檢測到感染疾病監測和移植監測，高解析度診斷和整合資料工作流程在整個臨床流程中的應用，正在重塑醫療決策。同時，貿易政策的變化和區域產能差異等外部壓力凸顯了建構具有韌性的供應鏈、在地檢驗和彈性部署策略的必要性。

目錄

第1章：序言

第2章：調查方法

  • 調查設計
  • 研究框架
  • 市場規模預測
  • 數據三角測量
  • 調查結果
  • 調查的前提
  • 研究限制

第3章執行摘要

  • 首席體驗長觀點
  • 市場規模和成長趨勢
  • 2025年市佔率分析
  • FPNV定位矩陣，2025
  • 新的商機
  • 下一代經營模式
  • 產業藍圖

第4章 市場概覽

  • 產業生態系與價值鏈分析
  • 波特五力分析
  • PESTEL 分析
  • 市場展望
  • 上市策略

第5章 市場洞察

  • 消費者洞察與終端用戶觀點
  • 消費者體驗基準
  • 機會映射
  • 分銷通路分析
  • 價格趨勢分析
  • 監理合規和標準框架
  • ESG與永續性分析
  • 中斷和風險情景
  • 投資報酬率和成本效益分析

第6章：美國關稅的累積影響，2025年

第7章：人工智慧的累積影響，2025年

第8章 按診斷應用分類的移植診斷市場

  • 供者相容性評估
  • 移植監測
  • HLA型檢測
    • 高解析度
    • 低解析度
  • 傳染病篩檢
    • 細菌篩檢
    • 真菌篩檢
    • 病毒篩檢
      • 巨細胞病毒
      • EB病毒
      • 肝炎病毒
      • HIV

第9章 移植診斷市場：依技術分類

  • 酵素法
  • 流式細胞技術
  • PCR
    • 數位PCR
    • QPCR
  • 定序
    • 新一代
    • 桑格

第10章 按器官分類的移植診斷市場

  • 心
  • 腎
  • 肝
  • 肺
  • 胰臟

第11章 移植診斷市場：依最終使用者分類

  • 診斷檢查室
  • 醫院
    • 私立醫院
    • 公立醫院
  • 研究機構
  • 移植中心

第12章 移植診斷市場：依地區分類

  • 北美洲和南美洲
    • 北美洲
    • 拉丁美洲
  • 歐洲、中東和非洲
    • 歐洲
    • 中東
    • 非洲
  • 亞太地區

第13章 移植診斷市場：依組別分類

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第14章 移植診斷市場：依國家分類

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

第15章：美國移植診斷市場

第16章：中國移植診斷市場

第17章 競爭格局

  • 市場集中度分析，2025年
    • 濃度比（CR）
    • 赫芬達爾-赫希曼指數 (HHI)
  • 近期趨勢及影響分析，2025 年
  • 2025年產品系列分析
  • 基準分析，2025 年
  • Abbott Laboratories
  • Adaptive Biotechnologies Corporation
  • altona Diagnostics GmbH
  • Arquer Diagnostics Ltd.
  • BAG Group
  • Becton, Dickinson and Company
  • Bio-Rad Laboratories, Inc.
  • Biogenuix Medsystems Pvt. Ltd
  • BioMerieux SA
  • Bruker Corporation
  • Caredx Inc.
  • CareDx, Inc.
  • CLONIT srl
  • Diagnostica Longwood SL
  • DiaSorin SpA
  • Eurofins Scientific SE
  • F. Hoffmann-La Roche Ltd.
  • Genome Diagnostics BV
  • Hologic, Inc.
  • Illumina, Inc
  • Immucor, Inc.
  • Laboratory Corporation of America Holdings
  • Luminex Corporation
  • Merck KGaA
  • NanoString Technologies, Inc.
  • Novartis AG
  • PathoNostics BV
  • QIAGEN, NV
  • Quest Diagnostics Incorporated
  • Randox Laboratories Ltd.
  • Takara Bio Inc.
  • Thermo Fisher Scientific Inc.
  • TransMedics, Inc.
  • Zimmer Biomet Group
Product Code: MRR-031685195790

The Transplant Diagnostics Market was valued at USD 6.78 billion in 2025 and is projected to grow to USD 7.20 billion in 2026, with a CAGR of 7.03%, reaching USD 10.92 billion by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 6.78 billion
Estimated Year [2026] USD 7.20 billion
Forecast Year [2032] USD 10.92 billion
CAGR (%) 7.03%

A comprehensive introduction to transplant diagnostics that explains the convergence of molecular innovation, clinical workflows, and regulatory imperatives guiding care pathways

Transplant diagnostics occupies a pivotal intersection of immunology, molecular biology, and clinical workflow optimization, where rapid and reliable diagnostics underpin patient outcomes and program sustainability. Recent advances in molecular assays, next-generation sequencing, and digital PCR have expanded the diagnostic toolkit available to clinicians and laboratory directors, enabling more precise donor-recipient matching, earlier detection of graft injury, and refined pathogen surveillance. These technological improvements are complemented by operational trends that emphasize faster turnaround, automated data integration, and scalable laboratory models that can support high-throughput testing without sacrificing analytical rigor.

Consequently, stakeholders from transplant centers to diagnostic laboratories are recalibrating clinical pathways and procurement processes to capture the clinical value of advanced diagnostics while managing cost and complexity. In parallel, regulatory attention on assay validation, data integrity, and interoperability is intensifying, which drives a greater need for standardized workflows and evidence generation. As a result, leaders must weigh the clinical benefits of novel assays against implementation realities, aligning stakeholders across clinical, laboratory, and administrative functions to ensure that diagnostic innovations translate into measurable improvements in graft survival and patient safety.

How emerging molecular platforms, digital integration, and collaborative evidence generation are reshaping clinical practice and adoption pathways in transplant diagnostics

The landscape of transplant diagnostics is shifting as emerging technologies, data-centric care models, and evolving clinical protocols converge to redefine standard practice. First, molecular diagnostics are moving from single-analyte tests toward multiplexed and sequencing-based approaches that deliver richer immunogenetic and pathogen profiles. This transition is changing how transplant teams approach donor selection, immunosuppression management, and post-transplant surveillance, because clinicians now have access to longitudinal biomarker trajectories rather than isolated snapshots.

Second, laboratory automation and digital integration are reducing manual variability and shortening test turnaround times, which supports more dynamic clinical decision-making. As a result, transplant programs are able to adopt more proactive monitoring regimens that detect graft injury earlier and enable timely therapeutic adjustments. Third, the regulatory and reimbursement environment is evolving to address clinical utility and evidence thresholds for novel diagnostics, prompting manufacturers and health systems to invest in real-world evidence studies and payer engagement. Finally, partnerships between diagnostics firms, clinical centers, and data platforms are accelerating the development of companion diagnostics and standardized reporting frameworks, which together lower barriers to adoption and create pathways for scalable implementation across diverse healthcare settings.

Evaluating the operational and supply chain repercussions of recent United States tariff measures on transplant diagnostics procurement, manufacturing, and clinical workflows

In 2025, tariff policies introduced in the United States have introduced an additional layer of complexity for manufacturers, laboratories, and clinical programs that rely on global supply chains. Import-dependent components, including specialized reagents, instrumentation parts, and sequencing consumables, face increased procurement costs and disrupted sourcing timelines. As an immediate consequence, laboratory managers have had to reassess vendor relationships, diversify supplier networks, and in some cases prioritize inventory safety stock to preserve continuity of testing services.

At the same time, manufacturers are responding by rationalizing regional manufacturing footprints and accelerating localization efforts to mitigate exposure to tariff-related volatility. These adjustments often require substantial capital investment and longer lead times to realize cost benefits. Meanwhile, clinical programs that operate under fixed reimbursement regimes feel pressure on operating margins, prompting tighter prioritization of test utilization and greater scrutiny over cost-effectiveness. In response, many stakeholders are adopting strategic sourcing strategies and reengineering workflows to optimize batch processing and consolidate testing where clinically appropriate. Over the medium term, supply chain resilience, supplier diversification, and contractual flexibility will become essential capabilities for organizations seeking to maintain service continuity and manage the financial impacts of trade policy shifts.

Insightful segmentation analysis revealing how diagnostic application, technological modality, organ-specific needs, and end-user structures shape adoption and investment priorities

A granular understanding of market segments provides actionable insight into where clinical demand and technology adoption are diverging. When viewed through diagnostic application lenses, donor and recipient matching, graft monitoring, HLA typing, and infectious disease screening occupy distinct clinical pathways with different analytical priorities. HLA typing presents a duality of resolution needs where high-resolution assays enable precise allele-level matching for complex cases while low-resolution approaches continue to satisfy routine compatibility screening. Infectious disease screening spans bacterial, fungal, and viral domains, with viral surveillance itself requiring targeted assays for pathogens such as cytomegalovirus, Epstein-Barr virus, hepatitis viruses, and HIV, each of which imposes specific sensitivity and turnaround constraints on laboratories.

Technology segmentation further clarifies adoption trajectories: enzymatic assays and flow cytometry maintain foundational roles in many diagnostic workflows, while PCR modalities, including quantitative PCR and digital PCR, deliver high-sensitivity quantitation useful for viral load monitoring and minimal residual disease detection. Sequencing technologies, both next-generation and Sanger, are increasingly applied for HLA allele characterization and complex pathogen genotyping, yielding higher-resolution data that supports personalized immunosuppression strategies. Organ-type segmentation highlights differentiated clinical requirements across heart, kidney, liver, lung, and pancreas transplantation, where graft-specific biomarkers, monitoring frequency, and risk tolerances drive distinct testing patterns. Finally, end-user segmentation reveals the operational perspectives of diagnostic laboratories, hospitals, research institutes, and transplant centers; within hospitals, the distinction between private and public institutions affects procurement models, budgetary constraints, and adoption timelines. Together, these intersecting segmentations elucidate where investments in assay development, laboratory automation, and clinical validation will produce the greatest clinical and operational impact.

Regional intelligence detailing how clinical capacity, regulatory diversity, and supply chain dynamics drive differentiated adoption patterns across global healthcare markets

Regional dynamics are critical to understanding how clinical practice, regulatory frameworks, and reimbursement policies influence diagnostic adoption in transplant care. In the Americas, clinical networks and centralized laboratories often prioritize rapid molecular assays and streamlined supply channels, with major transplant centers serving as early adopters and reference hubs that influence national practices. In Europe, Middle East & Africa, heterogeneity in regulatory environments, reimbursement mechanisms, and laboratory infrastructure produces a wide spectrum of adoption rates, where pockets of advanced practice coexist with resource-constrained settings that emphasize cost-effective, robust assays. In the Asia-Pacific region, rapid investments in laboratory capacity, combined with growing clinical volumes and a focus on domestic manufacturing, are driving accelerated uptake of sequencing and PCR-based diagnostics, especially in urban tertiary centers.

Across these regions, interoperability, harmonized standards, and cross-border data sharing remain pivotal for multicenter studies and longitudinal surveillance programs. Consequently, regional strategies must reconcile global best practices with local regulatory realities and supply chain considerations, enabling scalable implementations that respect differences in clinical workflows and payer systems. Strategic regional partnerships and localized validation studies are effective mechanisms to bridge capability gaps and to translate innovative diagnostics into routine practice across diverse healthcare ecosystems.

Competitive landscape analysis emphasizing the interplay of specialized innovators, platform providers, and informatics solutions that determine market leadership and clinical adoption

Competitive dynamics in transplant diagnostics reflect a balance between specialized innovators and larger platform providers that offer integrated solutions spanning assays, instrumentation, and informatics. Niche firms often lead in assay innovation, delivering high-resolution HLA typing, targeted viral surveillance panels, and novel biomarker approaches that address specific unmet clinical needs. Larger entities, by contrast, leverage scale to invest in laboratory automation, global distribution networks, and regulatory programs that facilitate broader market penetration. Partnerships and strategic alliances between assay developers, instrument manufacturers, and clinical networks are increasingly common, providing a pathway to validate clinical utility and to accelerate adoption through established channels.

In parallel, software and informatics players are becoming critical competitive differentiators by enabling standardized reporting, longitudinal data visualization, and integration with electronic health records. These capabilities enhance clinical utility by converting raw assay outputs into actionable insights for transplant clinicians. As competition intensifies, intellectual property around proprietary assays, ease of integration with existing laboratory ecosystems, and the ability to demonstrate real-world clinical outcomes will determine which companies successfully capture preference among transplant centers and reference laboratories.

Actionable recommendations for diagnostics developers, laboratories, and clinical leaders to align evidence generation, interoperability, and resilient supply strategies with adoption goals

Industry leaders should prioritize evidence-generation, interoperability, and supply chain resilience to convert technological promise into routine clinical practice. First, sponsors of new diagnostics must invest in rigorous clinical validation studies and real-world evidence programs that demonstrate clinical utility across representative transplant populations and care settings. This approach accelerates clinician trust and payer engagement, while informing appropriate use guidelines. Second, vendors and laboratories should design for interoperability by adopting standardized reporting formats, APIs for electronic health records, and laboratory information system integrations that reduce implementation friction and enable scalable deployment across hospital networks.

Third, building flexible supply chains with multiple qualified suppliers, regional manufacturing contingencies, and inventory management strategies will mitigate the operational risk of external policy and logistics disruptions. Fourth, commercial strategies should emphasize value-based conversations with hospitals and payers, framing diagnostics in terms of clinical outcomes, workflow efficiency, and total cost of care. Finally, fostering collaborative pilots with transplant centers and research institutes creates an evidence-driven pathway for adoption and provides practical feedback loops that refine product design and service models.

A transparent and rigorous research methodology combining clinical literature, regulatory guidance, and frontline practitioner insights to support evidence-based conclusions

The research underpinning this executive summary synthesized peer-reviewed literature, regulatory guidance, public clinical guidelines, and recent industry disclosures to ensure a balanced, evidence-based perspective. Primary sources included clinical validation studies, assay performance reports, and technical white papers that describe assay methodologies and analytical characteristics. Regulatory documents and guidance statements were reviewed to capture evolving expectations for validation, reporting, and laboratory quality assurance. In addition, qualitative inputs from laboratory directors, transplant clinicians, and supply chain managers informed practical considerations around implementation, turnaround, and procurement.

Analytical rigor was maintained through cross-referencing technical claims against independent evaluations and by prioritizing data from multicenter studies and established clinical programs. Where real-world operational impacts were discussed, case examples and implementation lessons were used to illustrate common barriers and mitigation strategies. Methodological transparency is central to the report, and appendices detail inclusion criteria, source hierarchies, and limitations to support reproducibility and critical appraisal by technical audiences.

Concluding synthesis highlighting how technological maturation, operational resilience, and collaborative evidence generation will determine the clinical impact and adoption trajectory of transplant diagnostics

The convergence of advanced molecular technologies, enhanced laboratory automation, and heightened clinical expectations positions transplant diagnostics as a critical enabler of improved graft outcomes and patient safety. Throughout clinical pathways, from donor selection and HLA typing to infectious disease surveillance and graft monitoring, the adoption of higher-resolution assays and integrated data workflows is reshaping care decisions. At the same time, external pressures such as trade policy shifts and heterogeneous regional capabilities underscore the need for resilient supply chains, localized validation, and adaptable implementation strategies.

Moving forward, stakeholders who combine rigorous evidence generation, interoperable systems design, and strategic commercial engagement will be best positioned to translate diagnostic innovation into measurable clinical value. Cross-sector collaboration between assay developers, clinical centers, and informatics providers will accelerate this transition, enabling diagnostics to move from episodic testing toward continuous, data-driven monitoring that supports proactive patient management and improved long-term outcomes.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Porter's Five Forces Analysis
  • 4.4. PESTLE Analysis
  • 4.5. Market Outlook
    • 4.5.1. Near-Term Market Outlook (0-2 Years)
    • 4.5.2. Medium-Term Market Outlook (3-5 Years)
    • 4.5.3. Long-Term Market Outlook (5-10 Years)
  • 4.6. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Transplant Diagnostics Market, by Diagnostic Application

  • 8.1. Donor Recipient Matching
  • 8.2. Graft Monitoring
  • 8.3. Hla Typing
    • 8.3.1. High Resolution
    • 8.3.2. Low Resolution
  • 8.4. Infectious Disease Screening
    • 8.4.1. Bacterial Screening
    • 8.4.2. Fungal Screening
    • 8.4.3. Viral Screening
      • 8.4.3.1. Cytomegalovirus
      • 8.4.3.2. Epstein Barr Virus
      • 8.4.3.3. Hepatitis Viruses
      • 8.4.3.4. Hiv

9. Transplant Diagnostics Market, by Technology

  • 9.1. Enzymatic Assays
  • 9.2. Flow Cytometry
  • 9.3. Pcr
    • 9.3.1. Digital Pcr
    • 9.3.2. Qpcr
  • 9.4. Sequencing
    • 9.4.1. Next Generation
    • 9.4.2. Sanger

10. Transplant Diagnostics Market, by Organ Type

  • 10.1. Heart
  • 10.2. Kidney
  • 10.3. Liver
  • 10.4. Lung
  • 10.5. Pancreas

11. Transplant Diagnostics Market, by End User

  • 11.1. Diagnostic Laboratories
  • 11.2. Hospitals
    • 11.2.1. Private Hospitals
    • 11.2.2. Public Hospitals
  • 11.3. Research Institutes
  • 11.4. Transplant Centers

12. Transplant Diagnostics Market, by Region

  • 12.1. Americas
    • 12.1.1. North America
    • 12.1.2. Latin America
  • 12.2. Europe, Middle East & Africa
    • 12.2.1. Europe
    • 12.2.2. Middle East
    • 12.2.3. Africa
  • 12.3. Asia-Pacific

13. Transplant Diagnostics Market, by Group

  • 13.1. ASEAN
  • 13.2. GCC
  • 13.3. European Union
  • 13.4. BRICS
  • 13.5. G7
  • 13.6. NATO

14. Transplant Diagnostics Market, by Country

  • 14.1. United States
  • 14.2. Canada
  • 14.3. Mexico
  • 14.4. Brazil
  • 14.5. United Kingdom
  • 14.6. Germany
  • 14.7. France
  • 14.8. Russia
  • 14.9. Italy
  • 14.10. Spain
  • 14.11. China
  • 14.12. India
  • 14.13. Japan
  • 14.14. Australia
  • 14.15. South Korea

15. United States Transplant Diagnostics Market

16. China Transplant Diagnostics Market

17. Competitive Landscape

  • 17.1. Market Concentration Analysis, 2025
    • 17.1.1. Concentration Ratio (CR)
    • 17.1.2. Herfindahl Hirschman Index (HHI)
  • 17.2. Recent Developments & Impact Analysis, 2025
  • 17.3. Product Portfolio Analysis, 2025
  • 17.4. Benchmarking Analysis, 2025
  • 17.5. Abbott Laboratories
  • 17.6. Adaptive Biotechnologies Corporation
  • 17.7. altona Diagnostics GmbH
  • 17.8. Arquer Diagnostics Ltd.
  • 17.9. BAG Group
  • 17.10. Becton, Dickinson and Company
  • 17.11. Bio-Rad Laboratories, Inc.
  • 17.12. Biogenuix Medsystems Pvt. Ltd
  • 17.13. BioMerieux SA
  • 17.14. Bruker Corporation
  • 17.15. Caredx Inc.
  • 17.16. CareDx, Inc.
  • 17.17. CLONIT srl
  • 17.18. Diagnostica Longwood SL
  • 17.19. DiaSorin S.p.A.
  • 17.20. Eurofins Scientific SE
  • 17.21. F. Hoffmann-La Roche Ltd.
  • 17.22. Genome Diagnostics B.V.
  • 17.23. Hologic, Inc.
  • 17.24. Illumina, Inc
  • 17.25. Immucor, Inc.
  • 17.26. Laboratory Corporation of America Holdings
  • 17.27. Luminex Corporation
  • 17.28. Merck KGaA
  • 17.29. NanoString Technologies, Inc.
  • 17.30. Novartis AG
  • 17.31. PathoNostics B.V
  • 17.32. QIAGEN, N.V.
  • 17.33. Quest Diagnostics Incorporated
  • 17.34. Randox Laboratories Ltd.
  • 17.35. Takara Bio Inc.
  • 17.36. Thermo Fisher Scientific Inc.
  • 17.37. TransMedics, Inc.
  • 17.38. Zimmer Biomet Group

LIST OF FIGURES

  • FIGURE 1. GLOBAL TRANSPLANT DIAGNOSTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL TRANSPLANT DIAGNOSTICS MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 3. GLOBAL TRANSPLANT DIAGNOSTICS MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 4. GLOBAL TRANSPLANT DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC APPLICATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 5. GLOBAL TRANSPLANT DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL TRANSPLANT DIAGNOSTICS MARKET SIZE, BY ORGAN TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 7. GLOBAL TRANSPLANT DIAGNOSTICS MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL TRANSPLANT DIAGNOSTICS MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 9. GLOBAL TRANSPLANT DIAGNOSTICS MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL TRANSPLANT DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 11. UNITED STATES TRANSPLANT DIAGNOSTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 12. CHINA TRANSPLANT DIAGNOSTICS MARKET SIZE, 2018-2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL TRANSPLANT DIAGNOSTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL TRANSPLANT DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL TRANSPLANT DIAGNOSTICS MARKET SIZE, BY DONOR RECIPIENT MATCHING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL TRANSPLANT DIAGNOSTICS MARKET SIZE, BY DONOR RECIPIENT MATCHING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL TRANSPLANT DIAGNOSTICS MARKET SIZE, BY DONOR RECIPIENT MATCHING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL TRANSPLANT DIAGNOSTICS MARKET SIZE, BY GRAFT MONITORING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL TRANSPLANT DIAGNOSTICS MARKET SIZE, BY GRAFT MONITORING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL TRANSPLANT DIAGNOSTICS MARKET SIZE, BY GRAFT MONITORING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL TRANSPLANT DIAGNOSTICS MARKET SIZE, BY HLA TYPING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL TRANSPLANT DIAGNOSTICS MARKET SIZE, BY HLA TYPING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL TRANSPLANT DIAGNOSTICS MARKET SIZE, BY HLA TYPING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL TRANSPLANT DIAGNOSTICS MARKET SIZE, BY HLA TYPING, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL TRANSPLANT DIAGNOSTICS MARKET SIZE, BY HIGH RESOLUTION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL TRANSPLANT DIAGNOSTICS MARKET SIZE, BY HIGH RESOLUTION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL TRANSPLANT DIAGNOSTICS MARKET SIZE, BY HIGH RESOLUTION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL TRANSPLANT DIAGNOSTICS MARKET SIZE, BY LOW RESOLUTION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL TRANSPLANT DIAGNOSTICS MARKET SIZE, BY LOW RESOLUTION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL TRANSPLANT DIAGNOSTICS MARKET SIZE, BY LOW RESOLUTION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL TRANSPLANT DIAGNOSTICS MARKET SIZE, BY INFECTIOUS DISEASE SCREENING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL TRANSPLANT DIAGNOSTICS MARKET SIZE, BY INFECTIOUS DISEASE SCREENING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL TRANSPLANT DIAGNOSTICS MARKET SIZE, BY INFECTIOUS DISEASE SCREENING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL TRANSPLANT DIAGNOSTICS MARKET SIZE, BY INFECTIOUS DISEASE SCREENING, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL TRANSPLANT DIAGNOSTICS MARKET SIZE, BY BACTERIAL SCREENING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL TRANSPLANT DIAGNOSTICS MARKET SIZE, BY BACTERIAL SCREENING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL TRANSPLANT DIAGNOSTICS MARKET SIZE, BY BACTERIAL SCREENING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL TRANSPLANT DIAGNOSTICS MARKET SIZE, BY FUNGAL SCREENING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL TRANSPLANT DIAGNOSTICS MARKET SIZE, BY FUNGAL SCREENING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL TRANSPLANT DIAGNOSTICS MARKET SIZE, BY FUNGAL SCREENING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL TRANSPLANT DIAGNOSTICS MARKET SIZE, BY VIRAL SCREENING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL TRANSPLANT DIAGNOSTICS MARKET SIZE, BY VIRAL SCREENING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL TRANSPLANT DIAGNOSTICS MARKET SIZE, BY VIRAL SCREENING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL TRANSPLANT DIAGNOSTICS MARKET SIZE, BY VIRAL SCREENING, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL TRANSPLANT DIAGNOSTICS MARKET SIZE, BY CYTOMEGALOVIRUS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL TRANSPLANT DIAGNOSTICS MARKET SIZE, BY CYTOMEGALOVIRUS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL TRANSPLANT DIAGNOSTICS MARKET SIZE, BY CYTOMEGALOVIRUS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL TRANSPLANT DIAGNOSTICS MARKET SIZE, BY EPSTEIN BARR VIRUS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL TRANSPLANT DIAGNOSTICS MARKET SIZE, BY EPSTEIN BARR VIRUS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL TRANSPLANT DIAGNOSTICS MARKET SIZE, BY EPSTEIN BARR VIRUS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL TRANSPLANT DIAGNOSTICS MARKET SIZE, BY HEPATITIS VIRUSES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL TRANSPLANT DIAGNOSTICS MARKET SIZE, BY HEPATITIS VIRUSES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL TRANSPLANT DIAGNOSTICS MARKET SIZE, BY HEPATITIS VIRUSES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL TRANSPLANT DIAGNOSTICS MARKET SIZE, BY HIV, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL TRANSPLANT DIAGNOSTICS MARKET SIZE, BY HIV, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL TRANSPLANT DIAGNOSTICS MARKET SIZE, BY HIV, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL TRANSPLANT DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL TRANSPLANT DIAGNOSTICS MARKET SIZE, BY ENZYMATIC ASSAYS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL TRANSPLANT DIAGNOSTICS MARKET SIZE, BY ENZYMATIC ASSAYS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL TRANSPLANT DIAGNOSTICS MARKET SIZE, BY ENZYMATIC ASSAYS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL TRANSPLANT DIAGNOSTICS MARKET SIZE, BY FLOW CYTOMETRY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL TRANSPLANT DIAGNOSTICS MARKET SIZE, BY FLOW CYTOMETRY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL TRANSPLANT DIAGNOSTICS MARKET SIZE, BY FLOW CYTOMETRY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL TRANSPLANT DIAGNOSTICS MARKET SIZE, BY PCR, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL TRANSPLANT DIAGNOSTICS MARKET SIZE, BY PCR, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL TRANSPLANT DIAGNOSTICS MARKET SIZE, BY PCR, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL TRANSPLANT DIAGNOSTICS MARKET SIZE, BY PCR, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL TRANSPLANT DIAGNOSTICS MARKET SIZE, BY DIGITAL PCR, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL TRANSPLANT DIAGNOSTICS MARKET SIZE, BY DIGITAL PCR, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 58. GLOBAL TRANSPLANT DIAGNOSTICS MARKET SIZE, BY DIGITAL PCR, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 59. GLOBAL TRANSPLANT DIAGNOSTICS MARKET SIZE, BY QPCR, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 60. GLOBAL TRANSPLANT DIAGNOSTICS MARKET SIZE, BY QPCR, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 61. GLOBAL TRANSPLANT DIAGNOSTICS MARKET SIZE, BY QPCR, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 62. GLOBAL TRANSPLANT DIAGNOSTICS MARKET SIZE, BY SEQUENCING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 63. GLOBAL TRANSPLANT DIAGNOSTICS MARKET SIZE, BY SEQUENCING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 64. GLOBAL TRANSPLANT DIAGNOSTICS MARKET SIZE, BY SEQUENCING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 65. GLOBAL TRANSPLANT DIAGNOSTICS MARKET SIZE, BY SEQUENCING, 2018-2032 (USD MILLION)
  • TABLE 66. GLOBAL TRANSPLANT DIAGNOSTICS MARKET SIZE, BY NEXT GENERATION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 67. GLOBAL TRANSPLANT DIAGNOSTICS MARKET SIZE, BY NEXT GENERATION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 68. GLOBAL TRANSPLANT DIAGNOSTICS MARKET SIZE, BY NEXT GENERATION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 69. GLOBAL TRANSPLANT DIAGNOSTICS MARKET SIZE, BY SANGER, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 70. GLOBAL TRANSPLANT DIAGNOSTICS MARKET SIZE, BY SANGER, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 71. GLOBAL TRANSPLANT DIAGNOSTICS MARKET SIZE, BY SANGER, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 72. GLOBAL TRANSPLANT DIAGNOSTICS MARKET SIZE, BY ORGAN TYPE, 2018-2032 (USD MILLION)
  • TABLE 73. GLOBAL TRANSPLANT DIAGNOSTICS MARKET SIZE, BY HEART, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 74. GLOBAL TRANSPLANT DIAGNOSTICS MARKET SIZE, BY HEART, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 75. GLOBAL TRANSPLANT DIAGNOSTICS MARKET SIZE, BY HEART, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 76. GLOBAL TRANSPLANT DIAGNOSTICS MARKET SIZE, BY KIDNEY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 77. GLOBAL TRANSPLANT DIAGNOSTICS MARKET SIZE, BY KIDNEY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 78. GLOBAL TRANSPLANT DIAGNOSTICS MARKET SIZE, BY KIDNEY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 79. GLOBAL TRANSPLANT DIAGNOSTICS MARKET SIZE, BY LIVER, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 80. GLOBAL TRANSPLANT DIAGNOSTICS MARKET SIZE, BY LIVER, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 81. GLOBAL TRANSPLANT DIAGNOSTICS MARKET SIZE, BY LIVER, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 82. GLOBAL TRANSPLANT DIAGNOSTICS MARKET SIZE, BY LUNG, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 83. GLOBAL TRANSPLANT DIAGNOSTICS MARKET SIZE, BY LUNG, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 84. GLOBAL TRANSPLANT DIAGNOSTICS MARKET SIZE, BY LUNG, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 85. GLOBAL TRANSPLANT DIAGNOSTICS MARKET SIZE, BY PANCREAS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 86. GLOBAL TRANSPLANT DIAGNOSTICS MARKET SIZE, BY PANCREAS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 87. GLOBAL TRANSPLANT DIAGNOSTICS MARKET SIZE, BY PANCREAS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 88. GLOBAL TRANSPLANT DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 89. GLOBAL TRANSPLANT DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 90. GLOBAL TRANSPLANT DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 91. GLOBAL TRANSPLANT DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 92. GLOBAL TRANSPLANT DIAGNOSTICS MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 93. GLOBAL TRANSPLANT DIAGNOSTICS MARKET SIZE, BY HOSPITALS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 94. GLOBAL TRANSPLANT DIAGNOSTICS MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 95. GLOBAL TRANSPLANT DIAGNOSTICS MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 96. GLOBAL TRANSPLANT DIAGNOSTICS MARKET SIZE, BY PRIVATE HOSPITALS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 97. GLOBAL TRANSPLANT DIAGNOSTICS MARKET SIZE, BY PRIVATE HOSPITALS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 98. GLOBAL TRANSPLANT DIAGNOSTICS MARKET SIZE, BY PRIVATE HOSPITALS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 99. GLOBAL TRANSPLANT DIAGNOSTICS MARKET SIZE, BY PUBLIC HOSPITALS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 100. GLOBAL TRANSPLANT DIAGNOSTICS MARKET SIZE, BY PUBLIC HOSPITALS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 101. GLOBAL TRANSPLANT DIAGNOSTICS MARKET SIZE, BY PUBLIC HOSPITALS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 102. GLOBAL TRANSPLANT DIAGNOSTICS MARKET SIZE, BY RESEARCH INSTITUTES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 103. GLOBAL TRANSPLANT DIAGNOSTICS MARKET SIZE, BY RESEARCH INSTITUTES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 104. GLOBAL TRANSPLANT DIAGNOSTICS MARKET SIZE, BY RESEARCH INSTITUTES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 105. GLOBAL TRANSPLANT DIAGNOSTICS MARKET SIZE, BY TRANSPLANT CENTERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 106. GLOBAL TRANSPLANT DIAGNOSTICS MARKET SIZE, BY TRANSPLANT CENTERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 107. GLOBAL TRANSPLANT DIAGNOSTICS MARKET SIZE, BY TRANSPLANT CENTERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 108. GLOBAL TRANSPLANT DIAGNOSTICS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 109. AMERICAS TRANSPLANT DIAGNOSTICS MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 110. AMERICAS TRANSPLANT DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 111. AMERICAS TRANSPLANT DIAGNOSTICS MARKET SIZE, BY HLA TYPING, 2018-2032 (USD MILLION)
  • TABLE 112. AMERICAS TRANSPLANT DIAGNOSTICS MARKET SIZE, BY INFECTIOUS DISEASE SCREENING, 2018-2032 (USD MILLION)
  • TABLE 113. AMERICAS TRANSPLANT DIAGNOSTICS MARKET SIZE, BY VIRAL SCREENING, 2018-2032 (USD MILLION)
  • TABLE 114. AMERICAS TRANSPLANT DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 115. AMERICAS TRANSPLANT DIAGNOSTICS MARKET SIZE, BY PCR, 2018-2032 (USD MILLION)
  • TABLE 116. AMERICAS TRANSPLANT DIAGNOSTICS MARKET SIZE, BY SEQUENCING, 2018-2032 (USD MILLION)
  • TABLE 117. AMERICAS TRANSPLANT DIAGNOSTICS MARKET SIZE, BY ORGAN TYPE, 2018-2032 (USD MILLION)
  • TABLE 118. AMERICAS TRANSPLANT DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 119. AMERICAS TRANSPLANT DIAGNOSTICS MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 120. NORTH AMERICA TRANSPLANT DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 121. NORTH AMERICA TRANSPLANT DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 122. NORTH AMERICA TRANSPLANT DIAGNOSTICS MARKET SIZE, BY HLA TYPING, 2018-2032 (USD MILLION)
  • TABLE 123. NORTH AMERICA TRANSPLANT DIAGNOSTICS MARKET SIZE, BY INFECTIOUS DISEASE SCREENING, 2018-2032 (USD MILLION)
  • TABLE 124. NORTH AMERICA TRANSPLANT DIAGNOSTICS MARKET SIZE, BY VIRAL SCREENING, 2018-2032 (USD MILLION)
  • TABLE 125. NORTH AMERICA TRANSPLANT DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 126. NORTH AMERICA TRANSPLANT DIAGNOSTICS MARKET SIZE, BY PCR, 2018-2032 (USD MILLION)
  • TABLE 127. NORTH AMERICA TRANSPLANT DIAGNOSTICS MARKET SIZE, BY SEQUENCING, 2018-2032 (USD MILLION)
  • TABLE 128. NORTH AMERICA TRANSPLANT DIAGNOSTICS MARKET SIZE, BY ORGAN TYPE, 2018-2032 (USD MILLION)
  • TABLE 129. NORTH AMERICA TRANSPLANT DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 130. NORTH AMERICA TRANSPLANT DIAGNOSTICS MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 131. LATIN AMERICA TRANSPLANT DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 132. LATIN AMERICA TRANSPLANT DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 133. LATIN AMERICA TRANSPLANT DIAGNOSTICS MARKET SIZE, BY HLA TYPING, 2018-2032 (USD MILLION)
  • TABLE 134. LATIN AMERICA TRANSPLANT DIAGNOSTICS MARKET SIZE, BY INFECTIOUS DISEASE SCREENING, 2018-2032 (USD MILLION)
  • TABLE 135. LATIN AMERICA TRANSPLANT DIAGNOSTICS MARKET SIZE, BY VIRAL SCREENING, 2018-2032 (USD MILLION)
  • TABLE 136. LATIN AMERICA TRANSPLANT DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 137. LATIN AMERICA TRANSPLANT DIAGNOSTICS MARKET SIZE, BY PCR, 2018-2032 (USD MILLION)
  • TABLE 138. LATIN AMERICA TRANSPLANT DIAGNOSTICS MARKET SIZE, BY SEQUENCING, 2018-2032 (USD MILLION)
  • TABLE 139. LATIN AMERICA TRANSPLANT DIAGNOSTICS MARKET SIZE, BY ORGAN TYPE, 2018-2032 (USD MILLION)
  • TABLE 140. LATIN AMERICA TRANSPLANT DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 141. LATIN AMERICA TRANSPLANT DIAGNOSTICS MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 142. EUROPE, MIDDLE EAST & AFRICA TRANSPLANT DIAGNOSTICS MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 143. EUROPE, MIDDLE EAST & AFRICA TRANSPLANT DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 144. EUROPE, MIDDLE EAST & AFRICA TRANSPLANT DIAGNOSTICS MARKET SIZE, BY HLA TYPING, 2018-2032 (USD MILLION)
  • TABLE 145. EUROPE, MIDDLE EAST & AFRICA TRANSPLANT DIAGNOSTICS MARKET SIZE, BY INFECTIOUS DISEASE SCREENING, 2018-2032 (USD MILLION)
  • TABLE 146. EUROPE, MIDDLE EAST & AFRICA TRANSPLANT DIAGNOSTICS MARKET SIZE, BY VIRAL SCREENING, 2018-2032 (USD MILLION)
  • TABLE 147. EUROPE, MIDDLE EAST & AFRICA TRANSPLANT DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 148. EUROPE, MIDDLE EAST & AFRICA TRANSPLANT DIAGNOSTICS MARKET SIZE, BY PCR, 2018-2032 (USD MILLION)
  • TABLE 149. EUROPE, MIDDLE EAST & AFRICA TRANSPLANT DIAGNOSTICS MARKET SIZE, BY SEQUENCING, 2018-2032 (USD MILLION)
  • TABLE 150. EUROPE, MIDDLE EAST & AFRICA TRANSPLANT DIAGNOSTICS MARKET SIZE, BY ORGAN TYPE, 2018-2032 (USD MILLION)
  • TABLE 151. EUROPE, MIDDLE EAST & AFRICA TRANSPLANT DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 152. EUROPE, MIDDLE EAST & AFRICA TRANSPLANT DIAGNOSTICS MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 153. EUROPE TRANSPLANT DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 154. EUROPE TRANSPLANT DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 155. EUROPE TRANSPLANT DIAGNOSTICS MARKET SIZE, BY HLA TYPING, 2018-2032 (USD MILLION)
  • TABLE 156. EUROPE TRANSPLANT DIAGNOSTICS MARKET SIZE, BY INFECTIOUS DISEASE SCREENING, 2018-2032 (USD MILLION)
  • TABLE 157. EUROPE TRANSPLANT DIAGNOSTICS MARKET SIZE, BY VIRAL SCREENING, 2018-2032 (USD MILLION)
  • TABLE 158. EUROPE TRANSPLANT DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 159. EUROPE TRANSPLANT DIAGNOSTICS MARKET SIZE, BY PCR, 2018-2032 (USD MILLION)
  • TABLE 160. EUROPE TRANSPLANT DIAGNOSTICS MARKET SIZE, BY SEQUENCING, 2018-2032 (USD MILLION)
  • TABLE 161. EUROPE TRANSPLANT DIAGNOSTICS MARKET SIZE, BY ORGAN TYPE, 2018-2032 (USD MILLION)
  • TABLE 162. EUROPE TRANSPLANT DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 163. EUROPE TRANSPLANT DIAGNOSTICS MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 164. MIDDLE EAST TRANSPLANT DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 165. MIDDLE EAST TRANSPLANT DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 166. MIDDLE EAST TRANSPLANT DIAGNOSTICS MARKET SIZE, BY HLA TYPING, 2018-2032 (USD MILLION)
  • TABLE 167. MIDDLE EAST TRANSPLANT DIAGNOSTICS MARKET SIZE, BY INFECTIOUS DISEASE SCREENING, 2018-2032 (USD MILLION)
  • TABLE 168. MIDDLE EAST TRANSPLANT DIAGNOSTICS MARKET SIZE, BY VIRAL SCREENING, 2018-2032 (USD MILLION)
  • TABLE 169. MIDDLE EAST TRANSPLANT DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 170. MIDDLE EAST TRANSPLANT DIAGNOSTICS MARKET SIZE, BY PCR, 2018-2032 (USD MILLION)
  • TABLE 171. MIDDLE EAST TRANSPLANT DIAGNOSTICS MARKET SIZE, BY SEQUENCING, 2018-2032 (USD MILLION)
  • TABLE 172. MIDDLE EAST TRANSPLANT DIAGNOSTICS MARKET SIZE, BY ORGAN TYPE, 2018-2032 (USD MILLION)
  • TABLE 173. MIDDLE EAST TRANSPLANT DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 174. MIDDLE EAST TRANSPLANT DIAGNOSTICS MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 175. AFRICA TRANSPLANT DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 176. AFRICA TRANSPLANT DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 177. AFRICA TRANSPLANT DIAGNOSTICS MARKET SIZE, BY HLA TYPING, 2018-2032 (USD MILLION)
  • TABLE 178. AFRICA TRANSPLANT DIAGNOSTICS MARKET SIZE, BY INFECTIOUS DISEASE SCREENING, 2018-2032 (USD MILLION)
  • TABLE 179. AFRICA TRANSPLANT DIAGNOSTICS MARKET SIZE, BY VIRAL SCREENING, 2018-2032 (USD MILLION)
  • TABLE 180. AFRICA TRANSPLANT DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 181. AFRICA TRANSPLANT DIAGNOSTICS MARKET SIZE, BY PCR, 2018-2032 (USD MILLION)
  • TABLE 182. AFRICA TRANSPLANT DIAGNOSTICS MARKET SIZE, BY SEQUENCING, 2018-2032 (USD MILLION)
  • TABLE 183. AFRICA TRANSPLANT DIAGNOSTICS MARKET SIZE, BY ORGAN TYPE, 2018-2032 (USD MILLION)
  • TABLE 184. AFRICA TRANSPLANT DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 185. AFRICA TRANSPLANT DIAGNOSTICS MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 186. ASIA-PACIFIC TRANSPLANT DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 187. ASIA-PACIFIC TRANSPLANT DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 188. ASIA-PACIFIC TRANSPLANT DIAGNOSTICS MARKET SIZE, BY HLA TYPING, 2018-2032 (USD MILLION)
  • TABLE 189. ASIA-PACIFIC TRANSPLANT DIAGNOSTICS MARKET SIZE, BY INFECTIOUS DISEASE SCREENING, 2018-2032 (USD MILLION)
  • TABLE 190. ASIA-PACIFIC TRANSPLANT DIAGNOSTICS MARKET SIZE, BY VIRAL SCREENING, 2018-2032 (USD MILLION)
  • TABLE 191. ASIA-PACIFIC TRANSPLANT DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 192. ASIA-PACIFIC TRANSPLANT DIAGNOSTICS MARKET SIZE, BY PCR, 2018-2032 (USD MILLION)
  • TABLE 193. ASIA-PACIFIC TRANSPLANT DIAGNOSTICS MARKET SIZE, BY SEQUENCING, 2018-2032 (USD MILLION)
  • TABLE 194. ASIA-PACIFIC TRANSPLANT DIAGNOSTICS MARKET SIZE, BY ORGAN TYPE, 2018-2032 (USD MILLION)
  • TABLE 195. ASIA-PACIFIC TRANSPLANT DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 196. ASIA-PACIFIC TRANSPLANT DIAGNOSTICS MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 197. GLOBAL TRANSPLANT DIAGNOSTICS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 198. ASEAN TRANSPLANT DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 199. ASEAN TRANSPLANT DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 200. ASEAN TRANSPLANT DIAGNOSTICS MARKET SIZE, BY HLA TYPING, 2018-2032 (USD MILLION)
  • TABLE 201. ASEAN TRANSPLANT DIAGNOSTICS MARKET SIZE, BY INFECTIOUS DISEASE SCREENING, 2018-2032 (USD MILLION)
  • TABLE 202. ASEAN TRANSPLANT DIAGNOSTICS MARKET SIZE, BY VIRAL SCREENING, 2018-2032 (USD MILLION)
  • TABLE 203. ASEAN TRANSPLANT DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 204. ASEAN TRANSPLANT DIAGNOSTICS MARKET SIZE, BY PCR, 2018-2032 (USD MILLION)
  • TABLE 205. ASEAN TRANSPLANT DIAGNOSTICS MARKET SIZE, BY SEQUENCING, 2018-2032 (USD MILLION)
  • TABLE 206. ASEAN TRANSPLANT DIAGNOSTICS MARKET SIZE, BY ORGAN TYPE, 2018-2032 (USD MILLION)
  • TABLE 207. ASEAN TRANSPLANT DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 208. ASEAN TRANSPLANT DIAGNOSTICS MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 209. GCC TRANSPLANT DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 210. GCC TRANSPLANT DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 211. GCC TRANSPLANT DIAGNOSTICS MARKET SIZE, BY HLA TYPING, 2018-2032 (USD MILLION)
  • TABLE 212. GCC TRANSPLANT DIAGNOSTICS MARKET SIZE, BY INFECTIOUS DISEASE SCREENING, 2018-2032 (USD MILLION)
  • TABLE 213. GCC TRANSPLANT DIAGNOSTICS MARKET SIZE, BY VIRAL SCREENING, 2018-2032 (USD MILLION)
  • TABLE 214. GCC TRANSPLANT DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 215. GCC TRANSPLANT DIAGNOSTICS MARKET SIZE, BY PCR, 2018-2032 (USD MILLION)
  • TABLE 216. GCC TRANSPLANT DIAGNOSTICS MARKET SIZE, BY SEQUENCING, 2018-2032 (USD MILLION)
  • TABLE 217. GCC TRANSPLANT DIAGNOSTICS MARKET SIZE, BY ORGAN TYPE, 2018-2032 (USD MILLION)
  • TABLE 218. GCC TRANSPLANT DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 219. GCC TRANSPLANT DIAGNOSTICS MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 220. EUROPEAN UNION TRANSPLANT DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 221. EUROPEAN UNION TRANSPLANT DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 222. EUROPEAN UNION TRANSPLANT DIAGNOSTICS MARKET SIZE, BY HLA TYPING, 2018-2032 (USD MILLION)
  • TABLE 223. EUROPEAN UNION TRANSPLANT DIAGNOSTICS MARKET SIZE, BY INFECTIOUS DISEASE SCREENING, 2018-2032 (USD MILLION)
  • TABLE 224. EUROPEAN UNION TRANSPLANT DIAGNOSTICS MARKET SIZE, BY VIRAL SCREENING, 2018-2032 (USD MILLION)
  • TABLE 225. EUROPEAN UNION TRANSPLANT DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 226. EUROPEAN UNION TRANSPLANT DIAGNOSTICS MARKET SIZE, BY PCR, 2018-2032 (USD MILLION)
  • TABLE 227. EUROPEAN UNION TRANSPLANT DIAGNOSTICS MARKET SIZE, BY SEQUENCING, 2018-2032 (USD MILLION)
  • TABLE 228. EUROPEAN UNION TRANSPLANT DIAGNOSTICS MARKET SIZE, BY ORGAN TYPE, 2018-2032 (USD MILLION)
  • TABLE 229. EUROPEAN UNION TRANSPLANT DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 230. EUROPEAN UNION TRANSPLANT DIAGNOSTICS MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 231. BRICS TRANSPLANT DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 232. BRICS TRANSPLANT DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 233. BRICS TRANSPLANT DIAGNOSTICS MARKET SIZE, BY HLA TYPING, 2018-2032 (USD MILLION)
  • TABLE 234. BRICS TRANSPLANT DIAGNOSTICS MARKET SIZE, BY INFECTIOUS DISEASE SCREENING, 2018-2032 (USD MILLION)
  • TABLE 235. BRICS TRANSPLANT DIAGNOSTICS MARKET SIZE, BY VIRAL SCREENING, 2018-2032 (USD MILLION)
  • TABLE 236. BRICS TRANSPLANT DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 237. BRICS TRANSPLANT DIAGNOSTICS MARKET SIZE, BY PCR, 2018-2032 (USD MILLION)
  • TABLE 238. BRICS TRANSPLANT DIAGNOSTICS MARKET SIZE, BY SEQUENCING, 2018-2032 (USD MILLION)
  • TABLE 239. BRICS TRANSPLANT DIAGNOSTICS MARKET SIZE, BY ORGAN TYPE, 2018-2032 (USD MILLION)
  • TABLE 240. BRICS TRANSPLANT DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 241. BRICS TRANSPLANT DIAGNOSTICS MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 242. G7 TRANSPLANT DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 243. G7 TRANSPLANT DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 244. G7 TRANSPLANT DIAGNOSTICS MARKET SIZE, BY HLA TYPING, 2018-2032 (USD MILLION)
  • TABLE 245. G7 TRANSPLANT DIAGNOSTICS MARKET SIZE, BY INFECTIOUS DISEASE SCREENING, 2018-2032 (USD MILLION)
  • TABLE 246. G7 TRANSPLANT DIAGNOSTICS MARKET SIZE, BY VIRAL SCREENING, 2018-2032 (USD MILLION)
  • TABLE 247. G7 TRANSPLANT DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 248. G7 TRANSPLANT DIAGNOSTICS MARKET SIZE, BY PCR, 2018-2032 (USD MILLION)
  • TABLE 249. G7 TRANSPLANT DIAGNOSTICS MARKET SIZE, BY SEQUENCING, 2018-2032 (USD MILLION)
  • TABLE 250. G7 TRANSPLANT DIAGNOSTICS MARKET SIZE, BY ORGAN TYPE, 2018-2032 (USD MILLION)
  • TABLE 251. G7 TRANSPLANT DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 252. G7 TRANSPLANT DIAGNOSTICS MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 253. NATO TRANSPLANT DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 254. NATO TRANSPLANT DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 255. NATO TRANSPLANT DIAGNOSTICS MARKET SIZE, BY HLA TYPING, 2018-2032 (USD MILLION)
  • TABLE 256. NATO TRANSPLANT DIAGNOSTICS MARKET SIZE, BY INFECTIOUS DISEASE SCREENING, 2018-2032 (USD MILLION)
  • TABLE 257. NATO TRANSPLANT DIAGNOSTICS MARKET SIZE, BY VIRAL SCREENING, 2018-2032 (USD MILLION)
  • TABLE 258. NATO TRANSPLANT DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 259. NATO TRANSPLANT DIAGNOSTICS MARKET SIZE, BY PCR, 2018-2032 (USD MILLION)
  • TABLE 260. NATO TRANSPLANT DIAGNOSTICS MARKET SIZE, BY SEQUENCING, 2018-2032 (USD MILLION)
  • TABLE 261. NATO TRANSPLANT DIAGNOSTICS MARKET SIZE, BY ORGAN TYPE, 2018-2032 (USD MILLION)
  • TABLE 262. NATO TRANSPLANT DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 263. NATO TRANSPLANT DIAGNOSTICS MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 264. GLOBAL TRANSPLANT DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 265. UNITED STATES TRANSPLANT DIAGNOSTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 266. UNITED STATES TRANSPLANT DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 267. UNITED STATES TRANSPLANT DIAGNOSTICS MARKET SIZE, BY HLA TYPING, 2018-2032 (USD MILLION)
  • TABLE 268. UNITED STATES TRANSPLANT DIAGNOSTICS MARKET SIZE, BY INFECTIOUS DISEASE SCREENING, 2018-2032 (USD MILLION)
  • TABLE 269. UNITED STATES TRANSPLANT DIAGNOSTICS MARKET SIZE, BY VIRAL SCREENING, 2018-2032 (USD MILLION)
  • TABLE 270. UNITED STATES TRANSPLANT DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 271. UNITED STATES TRANSPLANT DIAGNOSTICS MARKET SIZE, BY PCR, 2018-2032 (USD MILLION)
  • TABLE 272. UNITED STATES TRANSPLANT DIAGNOSTICS MARKET SIZE, BY SEQUENCING, 2018-2032 (USD MILLION)
  • TABLE 273. UNITED STATES TRANSPLANT DIAGNOSTICS MARKET SIZE, BY ORGAN TYPE, 2018-2032 (USD MILLION)
  • TABLE 274. UNITED STATES TRANSPLANT DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 275. UNITED STATES TRANSPLANT DIAGNOSTICS MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 276. CHINA TRANSPLANT DIAGNOSTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 277. CHINA TRANSPLANT DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 278. CHINA TRANSPLANT DIAGNOSTICS MARKET SIZE, BY HLA TYPING, 2018-2032 (USD MILLION)
  • TABLE 279. CHINA TRANSPLANT DIAGNOSTICS MARKET SIZE, BY INFECTIOUS DISEASE SCREENING, 2018-2032 (USD MILLION)
  • TABLE 280. CHINA TRANSPLANT DIAGNOSTICS MARKET SIZE, BY VIRAL SCREENING, 2018-2032 (USD MILLION)
  • TABLE 281. CHINA TRANSPLANT DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 282. CHINA TRANSPLANT DIAGNOSTICS MARKET SIZE, BY PCR, 2018-2032 (USD MILLION)
  • TABLE 283. CHINA TRANSPLANT DIAGNOSTICS MARKET SIZE, BY SEQUENCING, 2018-2032 (USD MILLION)
  • TABLE 284. CHINA TRANSPLANT DIAGNOSTICS MARKET SIZE, BY ORGAN TYPE, 2018-2032 (USD MILLION)
  • TABLE 285. CHINA TRANSPLANT DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 286. CHINA TRANSPLANT DIAGNOSTICS MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)